Track NeuroPace, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

NeuroPace, Inc. NPCE · Stock Open NeuroPace, Inc. in new tab

7.56 USD
EPS
-0.57
P/B
35.30
ROE
-103.27
Beta
1.93
Target Price
20.00 USD
Loading chart...
Key Metrics
Earnings dateMarch 2, 2027
EPS-0.57
Book Value0.35
Price to Book35.30
Debt/Equity588.50
% Insiders4.465%
Growth
Revenue Growth0.17%
Estimates
Forward P/E-56.32
Forward EPS-0.22
Target Mean Price20.00

DCF valuation

Model fair value for NeuroPace, Inc. (NPCE)
Result
Sign in to run the valuation for NPCE.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus None · mean target 20.00 USD (low 18.00, high 22.00) · as of 12 Nov 2026
Low 18.00
Mean 20.00
High 22.00
Price 7.56
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

NeuroPace, Inc. Logo NeuroPace, Inc. Analysis (NPCE)

United States Health Care Official Website Stock

Is NeuroPace, Inc. a good investment? NeuroPace, Inc. (NPCE) is currently trading at 7.56 USD. Market analysts have a consensus price target of 20.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: NeuroPace, Inc. is expected to release its next earnings report on March 2, 2027. The market consensus estimate for Forward EPS is -0.22.

Investor FAQ

Does NeuroPace, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is NeuroPace, Inc.?

NeuroPace, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 2, 2027. The company currently has a trailing EPS of -0.57.

Company Profile

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Exchange Ticker
NMS (United States) NPCE
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion